3D printing is not a new concept. It dates back to the 1980s. Not only has it revolutionized the manufacturing industry, but it has also impacted other industries such as construction, space travel, and healthcare. In the medical field, 3D printing is being extensively used by orthopedics, pediatrics, radiology, oncology, and other departments for the manufacture of prosthetics, replacement organs, and medical equipment.
3D printing is an additive manufacturing method in which a digital blueprint is followed to create a 3-dimensional object, layer-by-layer, using materials such as metals, plastics, and ceramics.
While there are 3D printing companies printing these objects on a large-scale basis, on-demand production of medical products is happening at the site of patient care in what is called point-of-care manufacturing. These products are manufactured as per the patient’s physical and personal requirements. They are lighter, stronger, and safer compared to those made using traditional manufacturing methods. Their production requires less time – what used to take weeklong to produce, now takes less than a day. Today, the number of hospitals with in-house 3D printing facilities is steadily increasing. In the U.S., the numbers of hospitals rose from 5754 in 2010 to 6093 in 2020, as per the statistics by the American Hospital Association (AHA) (see Figure 1). Even the FDA has been regularly approving medical products made using 3D printing technology.According to reports, the 3D-printed dental implants industry is set to attain nearly USD 8.8 billion by the end of 2027 with over 450 million dentistry devices and restorations manufactured every year.
A 2020 report upheld the use of 3D anatomical models as surgical guides and stated that it reduced the surgical time by more than 60 minutes to 2.5 hours, resulting in savings of around USD 3,500 per surgery.
The pharmaceutical industry spends over USD 55 billion every year on research and development. With bioprinting, researchers can replicate organs and other parts of the human body to test the efficacy of a drug without having to experiment on an animal or a human body. Bioprinted tissues and organs are being widely used to increase the success rate of clinical trials, reducing the damage caused to animals, while streamlining and speeding up the entire R&D process.
3D printing poses oversight challenges because of the decentralized manufacturing of customized products such as 3D printing medical implants by organizations or individuals that may have limited knowledge of FDA regulations. The FDA works hard to ensure that manufacturers abide by ethical manufacturing practices and that the products meet safety standards. But, when 3D printing is done at the point of care, oversight can be challenging.
Asia Pacific region is making tremendous progress in the 3D printing market. It is projected to spend over USD 3.5 billion on 3D printing in the next couple of years and grow at the highest rate of 18.5%, compared to North America and Europe. Till recently, the region was reluctant to adopt 3D printing fully, but growing interest in the technology from manufacturing companies and the launch of many strategies and policies by the governments have driven several countries within the region to create a favorable habitat for the growth of 3D printing.
China is the leader in 3D printing among Asian countries. Its market was worth USD 1.75 billion in 2018. Apart from China, South Korea seems to be a huge market for 3D printing. There is still a lot of untapped potential for the large-scale adoption and growth of 3D printing in the Asia Pacific region.